Spots Global Cancer Trial Database for revumenib
Every month we try and update this database with for revumenib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | NCT06284486 | Acute Myeloid L... | Venetoclax Revumenib | 12 Years - | M.D. Anderson Cancer Center | |
| Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors | NCT05731947 | Colorectal Canc... Solid Tumors | Revumenib Chemotherapy | 18 Years - | Syndax Pharmaceuticals | |
| A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia | NCT05761171 | Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Mixe... | Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cytarabine Echocardiograph... Fludarabine Pho... Hydrocortisone ... Lumbar Puncture Methotrexate Multigated Acqu... Prednisolone Prednisone Revumenib Vincristine Sul... | 1 Month - 6 Years | Children's Oncology Group | |
| A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib | NCT06284486 | Acute Myeloid L... | Venetoclax Revumenib | 12 Years - | M.D. Anderson Cancer Center | |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | NCT04065399 | Acute Myeloid L... Acute Lymphobla... Mixed Lineage A... Mixed Phenotype... Acute Leukemia ... | revumenib cobicistat | 30 Days - | Syndax Pharmaceuticals | |
| Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene | NCT05886049 | Acute Myeloid L... Acute Myeloid L... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Cytarabine Daunorubicin Multigated Acqu... Revumenib Transthoracic E... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia | NCT06177067 | Refractory Acut... Relapsed Acute ... Acute Leukemia ... | Revumenib Venetoclax Azacitidine intrathecal (IT... Cytarabine Methotrexate | 1 Year - 30 Years | St. Jude Children's Research Hospital | |
| Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene | NCT05886049 | Acute Myeloid L... Acute Myeloid L... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Cytarabine Daunorubicin Multigated Acqu... Revumenib Transthoracic E... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia | NCT05761171 | Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Acute... Recurrent Mixed... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Acut... Refractory Mixe... | Biospecimen Col... Bone Marrow Asp... Calaspargase Pe... Cytarabine Echocardiograph... Fludarabine Pho... Hydrocortisone ... Lumbar Puncture Methotrexate Multigated Acqu... Prednisolone Prednisone Revumenib Vincristine Sul... | 1 Month - 6 Years | Children's Oncology Group | |
| Study of Radiolabeled Revumenib in Adults With Acute Leukemia | NCT05406817 | Acute Leukemia | Revumenib | 18 Years - | Syndax Pharmaceuticals | |
| Study of Radiolabeled Revumenib in Adults With Acute Leukemia | NCT05406817 | Acute Leukemia | Revumenib | 18 Years - | Syndax Pharmaceuticals | |
| Revumenib in Combination With 7+3 + Midostaurin in AML | NCT06313437 | Acute Myeloid L... AML, Adult AML With Gene M... AML Leukemia | Revumenib Midostaurin Cytarabine Daunorubicin | 18 Years - 75 Years | Dana-Farber Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
